BRAF NP_004324.2:p.V600K

Known as: Serine/Threonine-Protein Kinase B-raf Val600Lys, NP_004324.2:p.Val600Lys, BRAF p.Val600Lys 
A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by lysine.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BackgroundThe resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2017
2017
Heterogeneity of BRAF mutation in melanoma has been a controversial subject. Quantitative data on BRAF allele frequency (AF) are… (More)
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
INTRODUCTION Although the detection of BRAF p.V600E mutation by immunohistochemistry was clearly described in melanoma… (More)
Is this relevant?
2014
2014
In the past few years, the treatment of melanoma has been revolutionised by the approval of the CTLA-4 antibody, ipilimumab, and… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BackgroundThe approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
CONTEXT A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the… (More)
Is this relevant?
2012
2012
The presence of a BRAF mutation in a melanoma tumor predicts response to BRAF inhibitors; however, the biological characteristics… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?